Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy
Membranous nephropathy （MN） is a common pathological type of adult nephrotic syndrome. According to the etiology, MN is divided into idiopathic membranous nephropathy （IMN） and secondary membranous nephropathy （SMN）. IMN accounts for around 80% of MN patients. Glucocorticoid plus alkylating agents o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2024-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2024.01.010 |
| _version_ | 1797292733617930240 |
|---|---|
| author | Chao Zhang Hui Liao Rong-shan Li |
| author_facet | Chao Zhang Hui Liao Rong-shan Li |
| author_sort | Chao Zhang |
| collection | DOAJ |
| description | Membranous nephropathy （MN） is a common pathological type of adult nephrotic syndrome. According to the etiology, MN is divided into idiopathic membranous nephropathy （IMN） and secondary membranous nephropathy （SMN）. IMN accounts for around 80% of MN patients. Glucocorticoid plus alkylating agents or calcineurin inhibitors （CNIs） are frequently prescribed. However, carcinogenic risk of alkylating agents and a high recurrence of disease after the dosing of CNIs have limited the applications of these two types of drugs. In the pathogenesis of MN, B cells play an important role of acting as antigen presenting cells. Rituximab （RTX）, a novel immunosuppressive agent, is a monoclonal antibody specific to B cell surface antigen CD20. In many recent clinical studies, RTX alone or plus other drugs has demonstrated a definite efficacy for MN. Whether or not patients benefit more from a single drug or a combination therapy is yet to be determined. |
| first_indexed | 2024-03-07T20:01:35Z |
| format | Article |
| id | doaj.art-dfc8f5d9e1b442398e9ae62e2ae0152f |
| institution | Directory Open Access Journal |
| issn | 1671-2390 |
| language | zho |
| last_indexed | 2024-03-07T20:01:35Z |
| publishDate | 2024-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj.art-dfc8f5d9e1b442398e9ae62e2ae0152f2024-02-28T07:44:01ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902024-01-01241656910.3969/j.issn.1671-2390.2024.01.01020220628Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathyChao Zhang0Hui Liao1Rong-shan Li2Department of Nephrology, the Fifth Hospital of Shanxi Medical University, Taiyuan 030012, ChinaDepartment of Pharmacy, the Fifth Hospital of Shanxi Medical University, Taiyuan 030012, ChinaDepartment of Nephrology, the Fifth Hospital of Shanxi Medical University, Taiyuan 030012, ChinaMembranous nephropathy （MN） is a common pathological type of adult nephrotic syndrome. According to the etiology, MN is divided into idiopathic membranous nephropathy （IMN） and secondary membranous nephropathy （SMN）. IMN accounts for around 80% of MN patients. Glucocorticoid plus alkylating agents or calcineurin inhibitors （CNIs） are frequently prescribed. However, carcinogenic risk of alkylating agents and a high recurrence of disease after the dosing of CNIs have limited the applications of these two types of drugs. In the pathogenesis of MN, B cells play an important role of acting as antigen presenting cells. Rituximab （RTX）, a novel immunosuppressive agent, is a monoclonal antibody specific to B cell surface antigen CD20. In many recent clinical studies, RTX alone or plus other drugs has demonstrated a definite efficacy for MN. Whether or not patients benefit more from a single drug or a combination therapy is yet to be determined.http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2024.01.010membranous nephropathyrituximabphospholipase a2 receptors |
| spellingShingle | Chao Zhang Hui Liao Rong-shan Li Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy Linchuang shenzangbing zazhi membranous nephropathy rituximab phospholipase a2 receptors |
| title | Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy |
| title_full | Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy |
| title_fullStr | Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy |
| title_full_unstemmed | Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy |
| title_short | Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy |
| title_sort | therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy |
| topic | membranous nephropathy rituximab phospholipase a2 receptors |
| url | http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2024.01.010 |
| work_keys_str_mv | AT chaozhang therapeuticadvancesofrituximabaloneorplusotherdrugsformembranousnephropathy AT huiliao therapeuticadvancesofrituximabaloneorplusotherdrugsformembranousnephropathy AT rongshanli therapeuticadvancesofrituximabaloneorplusotherdrugsformembranousnephropathy |